ATE396206T1 - Antikörper gegen il-1 beta - Google Patents

Antikörper gegen il-1 beta

Info

Publication number: ATE396206T1
Authority: AT; Austria
Prior art keywords: beta; antibodies against; antibodies
Prior art date: 2000-08-22

Application number

AT01976118T

Other languages

English (en)

Inventor

Hermann Gram

Padova Franco Di

Original Assignee

Novartis Pharma Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-08-22

Filing date

2001-08-20

Publication date

2008-06-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9898090&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE396206(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2001-08-20 Application filed by Novartis Pharma Gmbh filed Critical Novartis Pharma Gmbh

2008-06-15 Application granted granted Critical

2008-06-15 Publication of ATE396206T1 publication Critical patent/ATE396206T1/de

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/245—IL-1
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Physical Education & Sports Medicine (AREA)
Diabetes (AREA)
Rheumatology (AREA)
Pulmonology (AREA)
Orthopedic Medicine & Surgery (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Dermatology (AREA)
Emergency Medicine (AREA)
Ophthalmology & Optometry (AREA)
Endocrinology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Cardiology (AREA)
Transplantation (AREA)
Urology & Nephrology (AREA)
Toxicology (AREA)
Gastroenterology & Hepatology (AREA)
Pain & Pain Management (AREA)

AT01976118T 2000-08-22 2001-08-20 Antikörper gegen il-1 beta ATE396206T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB0020685.4A GB0020685D0 (en)	2000-08-22	2000-08-22	Organic compounds

Publications (1)

Publication Number	Publication Date
ATE396206T1 true ATE396206T1 (de)	2008-06-15

Family

ID=9898090

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT01976118T ATE396206T1 (de)	2000-08-22	2001-08-20	Antikörper gegen il-1 beta

Country Status (37)

Country	Link
US (3)	US7446175B2 (de)
EP (1)	EP1313769B2 (de)
JP (2)	JP4271936B2 (de)
KR (2)	KR100910789B1 (de)
CN (1)	CN100547003C (de)
AR (1)	AR035581A1 (de)
AT (1)	ATE396206T1 (de)
AU (2)	AU9549001A (de)
BE (1)	BE2009C057I2 (de)
BR (1)	BR0113420A (de)
CA (1)	CA2420231C (de)
CY (2)	CY1108779T1 (de)
CZ (1)	CZ304470B6 (de)
DE (2)	DE122009000078I1 (de)
DK (1)	DK1313769T4 (de)
EC (1)	ECSP034490A (de)
ES (1)	ES2305110T5 (de)
FR (1)	FR09C0062I2 (de)
GB (1)	GB0020685D0 (de)
HK (1)	HK1061403A1 (de)
HU (2)	HU228159B1 (de)
IL (2)	IL154465A0 (de)
LU (1)	LU91624I2 (de)
MX (1)	MXPA03001590A (de)
MY (1)	MY130248A (de)
NL (1)	NL300427I2 (de)
NO (3)	NO332609B1 (de)
NZ (2)	NZ534269A (de)
PE (1)	PE20020319A1 (de)
PL (1)	PL212480B1 (de)
PT (1)	PT1313769E (de)
RU (1)	RU2286351C2 (de)
SI (1)	SI1313769T2 (de)
SK (1)	SK288089B6 (de)
TW (1)	TWI321568B (de)
WO (1)	WO2002016436A2 (de)
ZA (1)	ZA200301275B (de)

Families Citing this family (109)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2426710A1 (en) *	2000-11-08	2002-10-10	Human Genome Sciences, Inc.	Antibodies that immunospecifically bind to trail receptors
US7348003B2 (en)	2001-05-25	2008-03-25	Human Genome Sciences, Inc.	Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors
US7361341B2 (en)	2001-05-25	2008-04-22	Human Genome Sciences, Inc.	Methods of treating cancer using antibodies that immunospecifically bind to trail receptors
EA033750B1 (ru) *	2002-09-06	2019-11-21	Amgen Inc	Изолированная молекула нуклеиновой кислоты, кодирующая антитело человека к рецептору интерлейкина-1, и ее применение
US7101978B2 (en) *	2003-01-08	2006-09-05	Applied Molecular Evolution	TNF-α binding molecules
CA2509136C (en) *	2003-01-24	2013-10-29	Applied Molecular Evolution, Inc.	Human il-1 beta antagonists
GB0303337D0 (en)	2003-02-13	2003-03-19	Celltech R&D Ltd	Biological products
US20040224893A1 (en) *	2003-05-06	2004-11-11	Li-Hsien Wang	Methods of using IL-1 antagonists to treat neointimal hyperplasia
NZ549040A (en) *	2004-02-17	2009-07-31	Schering Corp	Use for interleukin-33 (IL33) and the IL-33 receptor complex
US7615212B2 (en) *	2004-02-26	2009-11-10	Baylor Research Institute	Compositions and methods for the systemic treatment of arthritis
US7566772B2 (en) *	2005-01-26	2009-07-28	Amgen Fremont Inc.	Antibodies against interleukin-1β
AU2012213934B9 (en) *	2005-01-26	2013-07-25	Amgen Fremont Inc.	Antibodies against interleukin-1 beta
GB0509512D0 (en) *	2005-05-10	2005-06-15	Novartis Ag	Organic compounds
SI2163562T1 (sl)	2005-06-21	2014-01-31	Xoma (Us) Llc	IL-1 beta vezavna protitelesa in njihovi fragmenti
JP2009511545A (ja) *	2005-10-14	2009-03-19	ノボ・ノルデイスク・エー／エス	Ｉｌ−１インヒビターを使用する糖尿病の治療
DK2848258T3 (en) *	2005-10-26	2018-03-19	Novartis Ag	Treatment of familial Mediterranean fever with anti-IL-1beta antibodies
KR20110079922A (ko)	2006-04-14	2011-07-11	노파르티스 아게	안과 장애 치료를 위한 ｉｌ－1 항체의 용도
JP5645409B2 (ja)	2006-12-20	2014-12-24	ゾーマ（ユーエス）リミテッドライアビリティカンパニー	ＩＬ−１β関連疾患の治療方法
CL2008001071A1 (es) *	2007-04-17	2009-05-22	Smithkline Beecham Corp	Metodo para obtener anticuerpo penta-especifico contra il-8/cxcl8, gro-alfa/cxcl1, gro-beta/cxcl2), gro-gama/cxcl3 y ena-78/cxcl5 humanas; anticuerpo penta-especifico; proceso de produccion del mismo; vector, hbridoma o celela que lo comprende; composicion farmceutica; uso para tratar copd, otras enfermedades.
EP1997832A1 (de) *	2007-05-29	2008-12-03	Ganymed Pharmaceuticals AG	Monoklonale Antikörper gegen Claudin-18 zur Behandlung von Krebs
AU2008257520B2 (en)	2007-05-29	2012-04-05	Novartis Ag	New indications for anti- IL-I-beta therapy
PL2391650T3 (pl)	2007-12-20	2015-03-31	Xoma Us Llc	Sposoby leczenia dny
MX2010011955A (es)	2008-04-29	2011-01-21	Abbott Lab	Inmunoglobulinas de dominio variable doble y usos de las mismas.
RU2010153578A (ru)	2008-06-03	2012-07-20	Эбботт Лэборетриз (Us)	Иммуноглобулины с двойными вариабельными доменами и их применение
EP2297209A4 (de)	2008-06-03	2012-08-01	Abbott Lab	Dual-variable- domain-immunglobuline und ihre verwendungen
PT2293816E (pt) *	2008-06-06	2013-02-13	Xoma Technology Ltd	Métodos para o tratamento da artrite reumatoide
MX2010014574A (es)	2008-07-08	2011-04-27	Abbott Lab	Inmunoglobulinas de dominio variable dual para prostaglandina e2 y usos de las mismas.
WO2010028275A1 (en) *	2008-09-05	2010-03-11	Xoma Technology Ltd.	METHODS FOR TREATING OR PREVENTING IL-1ß RELATED DISEASES
KR20110071011A (ko) *	2008-10-20	2011-06-27	아보트 러보러터리즈	Ｉｌ-18에 결합하는 항체 및 이의 정제 방법
US8298533B2 (en) *	2008-11-07	2012-10-30	Medimmune Limited	Antibodies to IL-1R1
EP2196476A1 (de)	2008-12-10	2010-06-16	Novartis Ag	Antikörperformulierung
WO2010128092A1 (en) *	2009-05-06	2010-11-11	Novartis Ag	ANTI-IL1-β ANTIBODY COMBINATION THERAPY
US8389474B1 (en) *	2009-07-14	2013-03-05	Alan Anson Wanderer	Rationale for IL-1 β targeted therapy to improve harvested organ viability, allograft tolerance, replant success and for conditions characterized by reduced or absent arterial perfusion
PE20121530A1 (es) *	2009-09-01	2012-12-22	Abbvie Inc	Inmunoglobulinas con dominio variable dual
AU2010306677B2 (en) *	2009-10-15	2013-05-23	Abbvie Inc.	Dual variable domain immunoglobulins and uses thereof
SI2493922T1 (sl)	2009-10-26	2017-06-30	F. Hoffmann-La Roche Ag	Postopek za proizvodnjo glikoziliranega imunoglobulina
UY32979A (es)	2009-10-28	2011-02-28	Abbott Lab	Inmunoglobulinas con dominio variable dual y usos de las mismas
JP5904645B2 (ja)	2010-05-07	2016-04-13	ゾーマ（ユーエス）リミテッドライアビリティカンパニー	ＩＬ−１β関連病態の治療のための方法
BR112013002578A2 (pt)	2010-08-03	2019-05-14	Abbvie Inc.	imunoglobinas de domínio variável duplo e usos das mesmas
KR20130139884A (ko)	2010-08-26	2013-12-23	애브비 인코포레이티드	이원 가변 도메인 면역글로불린 및 이의 용도
EP2697260A1 (de)	2011-04-15	2014-02-19	Merck Patent GmbH	Anti-il-1r1-inhibitoren zur verwendung bei krebs
US9707272B2 (en)	2011-07-12	2017-07-18	Universitat Zurich	Method for the treatment of acne by administering IL-1β antibody
DE102011083595A1 (de)	2011-09-28	2013-03-28	Bayer Pharma AG	Inhibition der Wirkung von Interleukin 1 beta zur Behandlung der Endometriose
BR112014007253A2 (pt) *	2011-09-30	2017-03-28	Novartis Ag	uso de anticorpos que se ligam a il-1beta
AP2014007680A0 (en)	2011-12-02	2014-06-30	Novartis Ag	Anti-1L-beta (interleukin-1beta) antibody-based prophylactic therapy to prevent complications leading to vaso-occlusion in sickle cell disease
CN107459576A (zh)	2011-12-14	2017-12-12	艾伯维德国有限责任两合公司	用于诊断和治疗铁相关病症的组合物和方法
US20140359902A1 (en)	2011-12-16	2014-12-04	Synthon Biopharmaceuticals B.V.	EXPRESSION OF SECRETORY IgA ANTIBODIES IN DUCKWEED
CN104144946A (zh)	2011-12-19	2014-11-12	爱克索马美国有限责任公司	治疗痤疮的方法
CA2861610A1 (en)	2011-12-30	2013-07-04	Abbvie Inc.	Dual specific binding proteins directed against il-13 and/or il-17
WO2013122544A2 (en)	2012-02-13	2013-08-22	Agency For Science, Technology And Research	IL-1β NEUTRALIZING HUMAN MONOCLONAL ANTIBODIES
CN103588878A (zh) *	2012-08-15	2014-02-19	江苏泰康生物医药有限公司	一种人源化抗人白细胞介素1 β单克隆抗体及其制备与应用
CA2890263C (en)	2012-11-01	2020-03-10	Abbvie Inc.	Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof
US9404930B2 (en)	2012-11-05	2016-08-02	Delenex Therapeutics Ag	Antibody to human IL-1 beta
AU2013344796B2 (en)	2012-11-16	2016-11-10	Novartis Ag	Use of IL-1 beta binding antibodies for treating peripheral arterial disease
ES2895848T3 (es)	2012-12-17	2022-02-22	Cell Medica Inc	Anticuerpos contra IL-1 beta
MX2015007931A (es)	2012-12-18	2015-10-05	Novartis Ag	Composiciones y metodos que utilizan una etiqueta de peptido que se une a hialuronano.
CN105324396A (zh)	2013-03-15	2016-02-10	艾伯维公司	针对IL-1β和/或IL-17的双重特异性结合蛋白
WO2015083120A1 (en)	2013-12-04	2015-06-11	Novartis Ag	USE OF IL-1β BINDING ANTIBODIES
US20170290876A1 (en)	2014-06-25	2017-10-12	Novartis Ag	Compositions and methods for long acting proteins
WO2015198240A2 (en)	2014-06-25	2015-12-30	Novartis Ag	Compositions and methods for long acting proteins
WO2016008851A1 (en) *	2014-07-14	2016-01-21	Boehringer Ingelheim International Gmbh	Anti-il-1b antibodies
MA41044A (fr)	2014-10-08	2017-08-15	Novartis Ag	Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
CN107001478B (zh)	2014-10-14	2022-01-11	诺华股份有限公司	针对pd-l1的抗体分子及其用途
AU2015345323A1 (en)	2014-11-10	2017-04-06	F. Hoffmann-La Roche Ag	Bispecific antibodies and methods of use in ophthalmology
KR20170082594A (ko)	2014-11-10	2017-07-14	에프. 호프만-라 로슈 아게	항-ang2 항체 및 사용 방법
US10093733B2 (en)	2014-12-11	2018-10-09	Abbvie Inc.	LRP-8 binding dual variable domain immunoglobulin proteins
JP2018516931A (ja)	2015-06-04	2018-06-28	ノバルティスアーゲー	末梢動脈疾患を処置するためのｉｌ−１ベータ結合抗体の使用
TW201710286A (zh)	2015-06-15	2017-03-16	艾伯維有限公司	抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
ES2878188T3 (es)	2015-07-29	2021-11-18	Novartis Ag	Terapias de combinación que comprenden moléculas de anticuerpos contra LAG-3
US20180207273A1 (en)	2015-07-29	2018-07-26	Novartis Ag	Combination therapies comprising antibody molecules to tim-3
CN108025051B (zh)	2015-07-29	2021-12-24	诺华股份有限公司	包含抗pd-1抗体分子的联合疗法
US20180371093A1 (en)	2015-12-17	2018-12-27	Novartis Ag	Antibody molecules to pd-1 and uses thereof
EP3426775A1 (de)	2016-03-10	2019-01-16	Novartis AG	Chemisch modifizierte mrna
CA3031346A1 (en)	2016-07-21	2018-01-25	Novartis Ag	Use of the il-1beta binding antibody canakinumab for treating or allevating symptoms of pulmonary sarcoidosis
EP3551047A1 (de)	2016-12-07	2019-10-16	Progenity, Inc.	Verfahren, vorrichtungen und systeme zur detektion des magen-darm-trakts
EP3554343A1 (de)	2016-12-14	2019-10-23	Progenity, Inc.	Behandlung einer erkrankung des gastrointestinaltraktes mit einem il-1-inhibitor
UY37758A (es)	2017-06-12	2019-01-31	Novartis Ag	Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos
WO2018235056A1 (en)	2017-06-22	2018-12-27	Novartis Ag	Il-1beta binding antibodies for use in treating cancer
WO2018234879A1 (en)	2017-06-22	2018-12-27	Novartis Ag	USE OF IL-1β BINDING ANTIBODIES IN THE TREATMENT OF CANCER
WO2019018441A1 (en) *	2017-07-17	2019-01-24	Massachusetts Institute Of Technology	ATLAS OF HEAVY AND ILLUMINATED HEAVY BARRIER TISSUE CELLS
WO2019038737A1 (en)	2017-08-25	2019-02-28	Novartis Ag	USE OF CANAKINUMAB
BR112020004903A2 (pt) *	2017-09-13	2020-09-15	Novartis Ag	uso de anticorpos de ligação de il-1b para o tratamento de hepatite alcoólica
RU2020119578A (ru)	2017-11-16	2021-12-17	Новартис Аг	Комбинированные терапии
CA3098277A1 (en) *	2018-05-09	2019-11-14	Novartis Ag	Use of canakinumab
EP3802611A2 (de)	2018-06-01	2021-04-14	Novartis AG	Bindungsmoleküle gegen bcma und deren verwendungen
AR116109A1 (es)	2018-07-10	2021-03-31	Novartis Ag	Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
GB2575853A (en) *	2018-07-25	2020-01-29	Robert Wotherspoon Hugh	IL-1ß binding antibody
CN110818793A (zh) *	2018-08-14	2020-02-21	中山康方生物医药有限公司	抗IL-1β的抗体、其药物组合物及其用途
WO2020039401A1 (en)	2018-08-24	2020-02-27	Novartis Ag	Treatment comprising il-1βeta binding antibodies and combinations thereof
US11976115B2 (en) *	2018-11-07	2024-05-07	Zeda Biopharmaceuticals, Inc.	Antibody binding to human IL-1β, preparation method therefor and use thereof
CA3120619A1 (en)	2018-11-19	2020-05-28	Progenity, Inc.	Methods and devices for treating a disease with biotherapeutics
BR112021011874A2 (pt)	2018-12-20	2021-09-08	Novartis Ag	Regime de dosagem e combinação farmacêutica compreendendo derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona
WO2020128613A1 (en)	2018-12-21	2020-06-25	Novartis Ag	Use of il-1beta binding antibodies
GB201901187D0 (en)	2019-01-29	2019-03-20	Autolus Ltd	Treatment of neurotoxicity and/or cytokine release syndrome
EP3924054B1 (de)	2019-02-15	2025-04-02	Novartis AG	3-(1-oxo-5- (piperidin-4-yl)isoindolin-2-yl)piperidin-2,6-dionderivate und ihre verwendungen
CN113329792B (zh)	2019-02-15	2024-06-28	诺华股份有限公司	取代的3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
WO2021116789A1 (en)	2019-12-09	2021-06-17	Novartis Ag	Anti-interleukin 1 beta antibodies for treatment of sickle cell disease
WO2021119482A1 (en)	2019-12-13	2021-06-17	Progenity, Inc.	Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
CA3165274A1 (en)	2019-12-20	2021-06-24	Novartis Ag	Combination of anti tim-3 antibody mbg453 and anti tgf-beta antibody nis793, with or without decitabine or the anti pd-1 antibody spartalizumab, for treating myelofibrosis and myelodysplastic syndrome
TWI793503B (zh) *	2020-01-20	2023-02-21	美商美國禮來大藥廠	抗IL-1β抗體
WO2021257539A1 (en) *	2020-06-16	2021-12-23	Academia Sinica	ANTIBODIES TO INTERLEUKIN-1β AND USES THEREOF
KR20230027056A (ko)	2020-06-23	2023-02-27	노파르티스 아게	3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법
WO2022023907A1 (en)	2020-07-31	2022-02-03	Novartis Ag	Methods of selecting and treating patients at elevated risk of major adverse cardiac events
WO2022097060A1 (en)	2020-11-06	2022-05-12	Novartis Ag	Cd19 binding molecules and uses thereof
WO2022167916A1 (en)	2021-02-03	2022-08-11	Novartis Ag	Use of il-1b binding antibodies for treating neuroinflammatory disorders
TW202304979A (zh)	2021-04-07	2023-02-01	瑞士商諾華公司	抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
AR125874A1 (es)	2021-05-18	2023-08-23	Novartis Ag	Terapias de combinación
JP2024519893A (ja)	2021-05-24	2024-05-21	ノバルティスアーゲー	変形性関節症の治療方法
IL308134A (en)	2021-06-22	2023-12-01	Novartis Ag	BISPECIFIC ANTIBODIES FOR USE IN THE TREATMENT OF HIDRADENITIS SUPPURATIVA

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US534858A (en) *		1895-02-26		Workman s time-recorder
CA1172789A (en)	1980-09-25	1984-08-14	Hideo Kasahara	POLYMERIC MATERIAL COMPRISING A POLYAMIDE BONDED TO A COPOLYMER CONTAINING AN IMIDE OF AN .alpha.,.beta. UNSATURATED CARBOXYLIC ACID
US4772685A (en)	1985-10-02	1988-09-20	Merck & Co., Inc.	Immunogenic peptides of human interleukin-1 and the corresponding anti-peptide antibodies
GB8601597D0 (en)	1986-01-23	1986-02-26	Wilson R H	Nucleotide sequences
US4935343A (en)	1986-08-08	1990-06-19	Syntex (U.S.A.) Inc.	Monoclonal antibodies for interleukin-1β
DE3785186T2 (de)	1986-09-02	1993-07-15	Enzon Lab Inc	Bindungsmolekuele mit einzelpolypeptidkette.
DK590387A (da)	1986-11-13	1988-05-14	Otsuka Pharma Co Ltd	Antistoffer mod interleukin-1
GB8717430D0 (en)	1987-07-23	1987-08-26	Celltech Ltd	Recombinant dna product
GB8809129D0 (en)	1988-04-18	1988-05-18	Celltech Ltd	Recombinant dna methods vectors and host cells
DE68925935T2 (de)	1988-10-01	1996-08-14	Otsuka Pharma Co Ltd	Antikörper gegen Interleukin-1-beta
GB8823869D0 (en)	1988-10-12	1988-11-16	Medical Res Council	Production of antibodies
FR2640146B1 (fr)	1988-12-08	1993-12-24	Commissariat A Energie Atomique	Anticorps monoclonaux anti-interleukines 1(alpha) et 1(beta), leur procede de production et applications desdits anticorps a la detection des interleukines 1(alpha) et 1(beta) et en therapeutique
IL162181A (en)	1988-12-28	2006-04-10	Pdl Biopharma Inc	A method of producing humanized immunoglubulin, and polynucleotides encoding the same
CA2018248A1 (en)	1989-06-07	1990-12-07	Clyde W. Shearman	Monoclonal antibodies against the human alpha/beta t-cell receptor, their production and use
US5859205A (en) *	1989-12-21	1999-01-12	Celltech Limited	Humanised antibodies
GB8928874D0 (en)	1989-12-21	1990-02-28	Celltech Ltd	Humanised antibodies
ATE356869T1 (de)	1990-01-12	2007-04-15	Amgen Fremont Inc	Bildung von xenogenen antikörpern
GB9014932D0 (en)	1990-07-05	1990-08-22	Celltech Ltd	Recombinant dna product and method
US5545806A (en)	1990-08-29	1996-08-13	Genpharm International, Inc.	Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en)	1990-08-29	1997-04-29	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
US5633425A (en)	1990-08-29	1997-05-27	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en)	1990-08-29	1997-08-26	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5770429A (en)	1990-08-29	1998-06-23	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
DE69127627T2 (de)	1990-08-29	1998-02-19	Genpharm Int	Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper
JP3714683B2 (ja) *	1992-07-30	2005-11-09	生化学工業株式会社	抗リウマチ剤
US5429614A (en)	1993-06-30	1995-07-04	Baxter International Inc.	Drug delivery system
WO1995001997A1 (en) *	1993-07-09	1995-01-19	Smithkline Beecham Corporation	RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN
US6309636B1 (en) *	1995-09-14	2001-10-30	Cancer Research Institute Of Contra Costa	Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides
US6051228A (en)	1998-02-19	2000-04-18	Bristol-Myers Squibb Co.	Antibodies against human CD40
GB0001448D0 (en)	2000-01-21	2000-03-08	Novartis Ag	Organic compounds

2000
- 2000-08-22 GB GBGB0020685.4A patent/GB0020685D0/en not_active Ceased
2001
- 2001-08-16 PE PE2001000817A patent/PE20020319A1/es not_active Application Discontinuation
- 2001-08-17 AR ARP010103946A patent/AR035581A1/es active IP Right Grant
- 2001-08-20 SI SI200130844T patent/SI1313769T2/sl unknown
- 2001-08-20 RU RU2003107564/13A patent/RU2286351C2/ru active Protection Beyond IP Right Term
- 2001-08-20 WO PCT/EP2001/009588 patent/WO2002016436A2/en active IP Right Grant
- 2001-08-20 KR KR1020037002161A patent/KR100910789B1/ko active IP Right Grant
- 2001-08-20 NZ NZ534269A patent/NZ534269A/en not_active IP Right Cessation
- 2001-08-20 DE DE122009000078C patent/DE122009000078I1/de active Pending
- 2001-08-20 CZ CZ2003-505A patent/CZ304470B6/cs unknown
- 2001-08-20 CA CA2420231A patent/CA2420231C/en not_active Expired - Lifetime
- 2001-08-20 IL IL15446501A patent/IL154465A0/xx unknown
- 2001-08-20 MX MXPA03001590A patent/MXPA03001590A/es active IP Right Grant
- 2001-08-20 US US10/362,082 patent/US7446175B2/en not_active Expired - Lifetime
- 2001-08-20 BR BR0113420-5A patent/BR0113420A/pt not_active IP Right Cessation
- 2001-08-20 AU AU9549001A patent/AU9549001A/xx active Pending
- 2001-08-20 DE DE60134148T patent/DE60134148D1/de not_active Expired - Lifetime
- 2001-08-20 SK SK213-2003A patent/SK288089B6/sk not_active IP Right Cessation
- 2001-08-20 AU AU2001295490A patent/AU2001295490B2/en active Active
- 2001-08-20 CN CNB018145140A patent/CN100547003C/zh not_active Expired - Lifetime
- 2001-08-20 EP EP01976118A patent/EP1313769B2/de not_active Expired - Lifetime
- 2001-08-20 NZ NZ524199A patent/NZ524199A/en not_active IP Right Cessation
- 2001-08-20 ES ES01976118T patent/ES2305110T5/es not_active Expired - Lifetime
- 2001-08-20 PL PL360358A patent/PL212480B1/pl unknown
- 2001-08-20 AT AT01976118T patent/ATE396206T1/de active
- 2001-08-20 PT PT01976118T patent/PT1313769E/pt unknown
- 2001-08-20 DK DK01976118.8T patent/DK1313769T4/da active
- 2001-08-20 HU HU0300806A patent/HU228159B1/hu active Protection Beyond IP Right Term
- 2001-08-20 KR KR1020087012282A patent/KR20080056316A/ko not_active Application Discontinuation
- 2001-08-20 JP JP2002521531A patent/JP4271936B2/ja not_active Expired - Lifetime
- 2001-08-21 MY MYPI20013927A patent/MY130248A/en unknown
- 2001-08-22 TW TW090120626A patent/TWI321568B/zh not_active IP Right Cessation
2003
- 2003-02-13 IL IL154465A patent/IL154465A/en active Protection Beyond IP Right Term
- 2003-02-17 ZA ZA200301275A patent/ZA200301275B/en unknown
- 2003-02-19 EC EC2003004490A patent/ECSP034490A/es unknown
- 2003-02-21 NO NO20030827A patent/NO332609B1/no not_active IP Right Cessation
2004
- 2004-04-29 HK HK04103018.8A patent/HK1061403A1/xx not_active IP Right Cessation
2008
- 2008-08-01 JP JP2008199799A patent/JP2008295456A/ja active Pending
- 2008-08-11 CY CY20081100840T patent/CY1108779T1/el unknown
- 2008-09-26 US US12/238,502 patent/US7993878B2/en not_active Expired - Fee Related
2009
- 2009-11-24 NL NL300427C patent/NL300427I2/nl unknown
- 2009-11-25 LU LU91624C patent/LU91624I2/fr unknown
- 2009-11-30 BE BE2009C057C patent/BE2009C057I2/fr unknown
- 2009-12-03 FR FR09C0062C patent/FR09C0062I2/fr active Active
- 2009-12-09 CY CY2009019C patent/CY2009019I2/el unknown
2011
- 2011-06-29 US US13/171,631 patent/US8273350B2/en not_active Expired - Fee Related
2012
- 2012-11-21 NO NO2012018C patent/NO2012018I1/no unknown
2013
- 2013-04-26 HU HUS1300015C patent/HUS1300015I1/hu unknown
2017
- 2017-10-11 NO NO2017052C patent/NO2017052I2/no unknown

Also Published As

Publication number	Publication date
PT1313769E (pt)	2008-08-26
JP2008295456A (ja)	2008-12-11
MXPA03001590A (es)	2003-06-04
WO2002016436A3 (en)	2002-06-20
IL154465A (en)	2010-11-30
DE122009000078I1 (de)	2010-03-25
KR20030034140A (ko)	2003-05-01
GB0020685D0 (en)	2000-10-11
ES2305110T3 (es)	2008-11-01
RU2286351C2 (ru)	2006-10-27
CY2009019I1 (el)	2012-01-25
EP1313769A2 (de)	2003-05-28
SI1313769T2 (sl)	2012-01-31
EP1313769B2 (de)	2011-11-09
US7446175B2 (en)	2008-11-04
BRPI0113420B1 (pt)	2002-02-28
DK1313769T3 (da)	2008-09-15
WO2002016436A2 (en)	2002-02-28
HUP0300806A2 (hu)	2003-12-29
BE2009C057I2 (de)	2021-01-28
KR100910789B1 (ko)	2009-08-04
AU2001295490B2 (en)	2005-06-16
BR0113420A (pt)	2003-07-29
CN1484652A (zh)	2004-03-24
CZ304470B6 (cs)	2014-05-21
AU9549001A (en)	2002-03-04
NZ534269A (en)	2006-04-28
CZ2003505A3 (cs)	2003-05-14
HUS1300015I1 (hu)	2021-05-28
EP1313769B1 (de)	2008-05-21
PL212480B1 (pl)	2012-10-31
HU228159B1 (en)	2013-01-28
SK288089B6 (sk)	2013-06-03
NL300427I1 (en)	2010-02-01
FR09C0062I2 (fr)	2010-12-31
FR09C0062I1 (de)	2010-08-01
NO2017052I1 (no)	2017-10-11
PE20020319A1 (es)	2002-06-11
MY130248A (en)	2007-06-29
NL300427I2 (en)	2010-02-01
CA2420231A1 (en)	2002-02-28
JP2004506448A (ja)	2004-03-04
SI1313769T1 (sl)	2008-10-31
IL154465A0 (en)	2003-09-17
CA2420231C (en)	2011-04-26
DE60134148D1 (de)	2008-07-03
US8273350B2 (en)	2012-09-25
ECSP034490A (es)	2003-03-31
JP4271936B2 (ja)	2009-06-03
PL360358A1 (en)	2004-09-06
BRPI0113420B8 (de)	2021-05-25
LU91624I2 (fr)	2010-01-25
NO20030827L (no)	2003-04-14
HK1061403A1 (en)	2004-09-17
SK2132003A3 (en)	2003-10-07
NZ524199A (en)	2004-09-24
CN100547003C (zh)	2009-10-07
NO332609B1 (no)	2012-11-19
LU91624I9 (de)	2018-11-19
TWI321568B (en)	2010-03-11
CY2009019I2 (el)	2017-07-12
ZA200301275B (en)	2004-04-02
HUP0300806A3 (en)	2005-09-28
CY1108779T1 (el)	2012-01-25
NO20030827D0 (no)	2003-02-21
NO2012018I2 (no)	2012-11-21
US20090081732A1 (en)	2009-03-26
NO2012018I1 (no)	2012-12-10
NO2017052I2 (no)	2018-05-14
AR035581A1 (es)	2004-06-16
KR20080056316A (ko)	2008-06-20
ES2305110T5 (es)	2012-03-13
US7993878B2 (en)	2011-08-09
US20110256151A1 (en)	2011-10-20
US20040063913A1 (en)	2004-04-01
DK1313769T4 (da)	2011-12-05

Publication	Publication Date	Title
ATE396206T1 (de)	2008-06-15	Antikörper gegen il-1 beta
HK1187932A1 (zh)	2014-04-17	抗體
ATE290000T1 (de)	2005-03-15	Muscarinagonisten
ATE252099T1 (de)	2003-11-15	Biarylcarboxamide
ATE426616T1 (de)	2009-04-15	Antikírper gegen menschliches mcp-1
DE50112518D1 (de)	2007-07-05	Windschott
ATA2932001A (de)	2004-11-15	Schneefräse
NO20030917L (no)	2003-04-16	Anvendelse
ATE262530T1 (de)	2004-04-15	Indolochinazolinone
DE60137387D1 (de)	2009-03-05	Verbindungsstruktur
NO20030276L (no)	2003-03-18	Fremgangsmåte
EE200300569A (et)	2004-04-15	CD44v6-spetsiifilised antikehad
AR028336A1 (es)	2003-05-07	4-hidroxi-tetrahidropiridonas fenilsubstituidas
DE50110284D1 (de)	2006-08-03	Drosselklappe
AR028061A1 (es)	2003-04-23	2-enamino-cetonitrilos fenil-substituidos
AR027931A1 (es)	2003-04-16	Antitranspirantes
DE50108130D1 (de)	2005-12-29	Drosselklappensteller
AR027982A1 (es)	2003-04-23	Aril- y heteroarilsulfonatos
DE60114278D1 (de)	2005-12-01	Kalenderuhr
FIU20000076U0 (fi)	2000-02-21	Kalanteri
ATE284887T1 (de)	2005-01-15	Thienopyrrolidinone
FI20000399A0 (fi)	2000-02-21	Kalanteri
AT500246B8 (de)	2007-02-15	Chokerring
FI4742U1 (fi)	2000-12-13	Kalanteri
ATA17542000A (de)	2002-08-15	Hydraulikzylinder